Drug Profile
BAY 858101
Alternative Names: BAY85-8101; F-18 FEDAA1106; ZK 6032924Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Radiopharmaceutical diagnostics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease; Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis) in Netherlands (IV, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis) in Sweden (IV, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-sclerosis(Diagnosis) in Australia (IV, Injection)